Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OPK – OPKO Health, Inc.

Float Short %

7.9

Margin Of Safety %

Put/Call OI Ratio

0.05

EPS Next Q Diff

-0.11

EPS Last/This Y

-0.25

EPS This/Next Y

0.02

Price

1.2

Target Price

3.56

Analyst Recom

1.57

Performance Q

-6.25

Upside

-829.2%

Beta

1.49

Ticker: OPK




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-23OPK1.3150.050.0126356
2026-01-26OPK1.2950.050.0026476
2026-01-27OPK1.2950.050.0026579
2026-01-28OPK1.270.050.0726563
2026-01-29OPK1.260.050.0226595
2026-01-30OPK1.260.050.0126487
2026-02-02OPK1.2850.050.0026564
2026-02-03OPK1.2650.050.0026781
2026-02-05OPK1.230.050.0826694
2026-02-09OPK1.2150.050.0026729
2026-02-10OPK1.2250.050.0026789
2026-02-11OPK1.2450.050.0226828
2026-02-12OPK1.2050.050.0026863
2026-02-13OPK1.230.050.0027187
2026-02-17OPK1.220.050.0127217
2026-02-18OPK1.210.050.0327764
2026-02-19OPK1.2050.050.0427967
2026-02-20OPK1.1950.050.0027915
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-23OPK1.32- - -0.33
2026-01-26OPK1.29- - -0.33
2026-01-27OPK1.29- - -0.33
2026-01-28OPK1.27- - -0.33
2026-01-29OPK1.26- - -0.33
2026-01-30OPK1.26- - -0.33
2026-02-02OPK1.29- - -0.33
2026-02-03OPK1.26- - -0.33
2026-02-04OPK1.25- - -0.33
2026-02-05OPK1.24- - -0.33
2026-02-06OPK1.24- - -0.33
2026-02-09OPK1.22- - -0.33
2026-02-10OPK1.22- - -0.33
2026-02-11OPK1.25- - -0.33
2026-02-12OPK1.21- - -0.33
2026-02-13OPK1.23- - -0.33
2026-02-17OPK1.22- - -0.33
2026-02-18OPK1.22- - -0.33
2026-02-19OPK1.21- - -0.33
2026-02-20OPK1.20- - -0.33
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-23OPK0.83-2.997.76
2026-01-26OPK0.83-2.947.76
2026-01-27OPK0.83-2.947.76
2026-01-28OPK0.83-2.947.80
2026-01-29OPK0.83-2.947.80
2026-01-30OPK0.83-2.947.80
2026-02-02OPK0.83-3.187.80
2026-02-03OPK0.83-3.187.80
2026-02-04OPK0.83-3.187.80
2026-02-05OPK0.83-3.187.80
2026-02-06OPK0.83-3.187.80
2026-02-09OPK0.65-3.977.80
2026-02-10OPK0.65-3.977.80
2026-02-11OPK0.65-3.977.90
2026-02-12OPK0.65-3.977.90
2026-02-13OPK0.65-3.977.90
2026-02-17OPK0.65-0.397.90
2026-02-18OPK0.65-0.397.90
2026-02-19OPK0.65-0.397.90
2026-02-20OPK0.65-0.397.90
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.03

Avg. EPS Est. Current Quarter

-0.07

Avg. EPS Est. Next Quarter

-0.08

Insider Transactions

0.65

Institutional Transactions

-0.39

Beta

1.49

Average Sales Estimate Current Quarter

139

Average Sales Estimate Next Quarter

130

Fair Value

Quality Score

46

Growth Score

30

Sentiment Score

23

Actual DrawDown %

77.1

Max Drawdown 5-Year %

-83.2

Target Price

3.56

P/E

Forward P/E

PEG

P/S

1.43

P/B

0.71

P/Free Cash Flow

EPS

-0.25

Average EPS Est. Cur. Y​

-0.33

EPS Next Y. (Est.)

-0.31

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-28.1

Relative Volume

0.4

Return on Equity vs Sector %

-42.8

Return on Equity vs Industry %

-24.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

Opko Health, Inc.
Sector: Healthcare
Industry: Diagnostics & Research
Employees: 2997
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offer laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test services. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, immunology, and infectious diseases; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins or peptides; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products for a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Spain, Ireland, Chile, and Mexico. OPKO Health, Inc. was founded in 2007 and is headquartered in Miami, Florida.
stock quote shares OPK – OPKO Health, Inc. Stock Price stock today
news today OPK – OPKO Health, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OPK – OPKO Health, Inc. yahoo finance google finance
stock history OPK – OPKO Health, Inc. invest stock market
stock prices OPK premarket after hours
ticker OPK fair value insiders trading